CNS Drugs

, Volume 26, Issue 10, pp 813–822

Further Findings Linking SSRIs During Pregnancy and Persistent Pulmonary Hypertension of the Newborn

Clinical Implications
  • Megan Galbally
  • Salvatore Gentile
  • Andrew J. Lewis
Current Opinion

DOI: 10.2165/11630310-000000000-00000

Cite this article as:
Galbally, M., Gentile, S. & Lewis, A.J. CNS Drugs (2012) 26: 813. doi:10.2165/11630310-000000000-00000

Abstract

Persistent pulmonary hypertension of the newborn (PPHN) is a rare but potentially life-threatening neonatal condition. Several authors have suggested that late pregnancy exposure to selective serotonin reuptake inhibitors (SSRIs) may increase the risk of PPHN. This association has been investigated in seven published studies that have shown mixed findings based on diverse methods. Several methodological limitations may account for the diversity of findings, which include, in some studies, a lack of control for well established risk factors for PPHN. The methodological improvement in the most recent study tentatively suggests that infants prenatally exposed to SSRIs are approximately twice as likely to suffer PPHN. Further research on the biological mechanisms involved is required. Clinicians should consider late pregnancy exposure to SSRIs as one of several possible risks for PPHN, which has implications for both prescribing SSRIs to pregnant women and for neonatal care of SSRI-exposed infants.

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Megan Galbally
    • 1
  • Salvatore Gentile
    • 2
    • 3
  • Andrew J. Lewis
    • 4
  1. 1.Mercy Hospital for WomenHeidelbergAustralia
  2. 2.Department of Mental HealthASL SalernoSalernoItaly
  3. 3.Department of Neurosciences, Medical School “Federico II”University of NaplesNaplesItaly
  4. 4.School of PsychologyDeakin UniversityBurwoodAustralia